21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer

The NSABP B-20 prospective-retrospective study of the 21-gene Oncotype DX Breast Cancer Recurrence Score® test predicted benefit from addition of chemotherapy to tamoxifen in node-negative, estrogen-receptor positive breast cancer when recurrence score (RS) was ≥31. HER2 is a component of the RS alg...

Descripción completa

Detalles Bibliográficos
Autores principales: Geyer, Charles E., Tang, Gong, Mamounas, Eleftherios P., Rastogi, Priya, Paik, Soonmyung, Shak, Steven, Baehner, Frederick L., Crager, Michael, Wickerham, D. Lawrence, Costantino, Joseph P., Wolmark, Norman
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235896/
https://www.ncbi.nlm.nih.gov/pubmed/30456299
http://dx.doi.org/10.1038/s41523-018-0090-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6235896/
https://www.ncbi.nlm.nih.gov/pubmed/30456299
http://dx.doi.org/10.1038/s41523-018-0090-6

Ejemplares similares